Acquiring the remaining rights to the CNS cancer drug patent solidifies Cosmos Health's position in the brain tumor market, which could lead to increased investor confidence and a positive impact on the stock price. The lack of disclosed financial terms introduces some uncertainty, but the strategic nature of the acquisition is likely to be viewed favorably.